দেশ: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
PERINDOPRIL ERBUMINE
LABORATOIRE RIVA INC.
C09AA04
PERINDOPRIL
2MG
TABLET
PERINDOPRIL ERBUMINE 2MG
ORAL
30/100
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0127178001; AHFS:
APPROVED
2018-03-07
_RIVA-PERINDOPRIL (Perindopril Erbumine Tablets) _ _ _ _Page 1 of 65_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR RIVA-PERINDOPRIL Perindopril Erbumine Tablets Tablets, 2 mg, 4 mg and 8 mg, Oral USP Angiotensin Converting Enzyme Inhibitor LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com Submission Control No.: 276450 Date of Initial Authorization: MAR 7, 2018 Date of Revision: JUL 13, 2023 _RIVA-PERINDOPRIL (Perindopril Erbumine Tablets) _ _ _ _Page 2 of 65_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 7 WARNING AND PRECAUTIONS TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics (< 18 years of age) .................................................................................... 4 1.2 Geriatrics (>65 years of age) ..................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ......................................................... 6 4.4 Administration ................................. সম্পূর্ণ নথি পড়ুন